---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-266040"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2026-06-10T21:08:54+00:00"
generated_at: "2026-06-10T21:10:16.119441+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tectonic completes enrollment in Phase 2 TX45 trial for PH-HFpEF; topline data expected early Q1 2027

## Summary
- APEX trial enrolled 191 patients across 14 countries; 72% (137 pts) in enriched CpcPH subset (PVR > 3 WU).
- Mean baseline PVR: 4.2 WU overall; 5.2 WU in CpcPH subset.
- Topline results from Phase 2 APEX study expected in early Q1 2027.
- Two dose regimens of TX45 (300 mg monthly or every other week) vs placebo; primary endpoint is change in PVR.

## SEC filing metadata
- accession: 0001193125-26-266040
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2026-06-10T21:08:54+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/0001193125-26-266040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/d124600d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-266040
- JSON: https://secwatch.observer/filing/0001193125-26-266040.json
- Plain text: https://secwatch.observer/filing/0001193125-26-266040.txt

## Key facts
- Shareholder Votes
  Tectonic Therapeutic, Inc. shareholders approved Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm at the 2026-06-08 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-08
  source text: Proposal 2: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,225,948 3,831 1,522 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/0001193125-26-266040-index.htm
- Shareholder Votes
  Tectonic Therapeutic, Inc. shareholders approved Election of Directors at the 2026-06-08 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-08
  source text: Proposal 1: Election of Directors Timothy A. Springer and Stefan Vitorovic were elected as Class II directors, to hold office until the 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows: Name of Director Elected Votes For Votes Withheld Broker Non-Votes Timothy A. Springer 11,461,485 2,963,750 2,806,066 Stefan Vitorovic 13,937,996 487,239 2,806,066
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/0001193125-26-266040-index.htm
- Shareholder Votes
  Tectonic Therapeutic, Inc. shareholders approved Advisory Approval on Executive Compensation at the 2026-06-08 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-08
  source text: Proposal 3: Advisory Approval on Executive Compensation The stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s Named Executive Officers, as disclosed in the Company’s proxy statement for the 2026 Annual Meeting. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 14,292,497 118,271 14,467 2,806,066
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000119312526266040/0001193125-26-266040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.